• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: DENTAL-AMALGAM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

DENTAL-AMALGAM Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Appropriate Clinical Signs, Symptoms, Conditions Term / Code Not Available (4581)
Event Type  Injury  
Event Description
I was diagnosed with multiple sclerosis and later believed to believe it because my dental amalgam mercury fillings as my identical twin did not have these fillings.This belief was later confirmed by the position statement sent out by the fda on sept, 24, 2020.It stated that caution should be taken in high-risk individuals (genetically - predisposed).This gives more validity between the connection between these mercury fillings and my ms.My twin should not get these fillings as it can unmask his latent ms.Fda safety report id # (b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
DENTAL-AMALGAM
Type of Device
DENTAL-AMALGAM
MDR Report Key14548346
MDR Text Key293147610
Report NumberMW5109994
Device Sequence Number1
Product Code OIV
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Patient
Type of Report Initial
Report Date 05/25/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Was Device Available for Evaluation? No
Initial Date Manufacturer Received Not provided
Initial Date FDA Received05/27/2022
Patient Sequence Number1
Treatment
TECHFIDERA - STOPPED AFTER < 1 YEAR OF USE; THE MERCURY REMOVAL PROCESS INVOLVES THE FOLLOWING: ALPHA LIPOIC ACID [TIMED RELEASE], A POWERFUL CHELATOR/ANTI-OXIDANT CAPABLE OF CROSSING THE BLOOD-BRAIN BARRIER AND BINDING TO MERCURY, COQ 10, VITAMINS A, B, C, D, AND E, MSM,SELENIUM, MAGNESIUM, LITHIUM, BORON, MILK THISTLE, TURMERIC, AND ZINC
Patient Outcome(s) Hospitalization; Other;
Patient Age34 YR
Patient SexMale
Patient Weight57 KG
Patient EthnicityNon Hispanic
Patient RaceAsian
-
-